Centre
Alzheimer’s, Dementia and Parkinson’s (ADP) Research Team
Unit(s) of assessment: Psychology, Psychiatry and Neuroscience
Research theme(s): Health Innovation
Overview
The Alzheimer’s, Dementia and Parkinson’s (ADP) research team at Nottingham Trent University is developing innovative approaches to improve the treatment, analysis and understanding of dementia and other neurodegenerative diseases.
Bringing together a multidisciplinary group of experts, the team is tackling one of the most urgent healthcare challenges of our time.
By combining expertise from various fields including chemical engineering, nanoscience and hydrogen production, the ADP team explores how ultrasound, ultraviolet light, radio frequencies and hydrogen can be used to break down biological barriers. This approach aims to enable more targeted treatment and more effective analysis of neurodegenerative disease.
Our research is driven by the belief that complex health challenges cannot be solved in isolation. Working collaboratively across disciplines allows us to address the devastating impact of neurodegenerative disease from multiple angles.
Based in state-of-the-art laboratories on NTU’s Clifton Campus, the team uses advanced facilities including high-speed, high-magnification video equipment that is critical to observational research. Our work spans key research themes such as health and wellbeing, medical technologies and advanced materials.
Funded by the Eranda Rothschild Foundation, the ADP team’s current research is structured around four interconnected project areas, each addressing a critical aspect of dementia research and the development of novel therapeutic strategies.
Project areas
Project area 1 focuses on investigating the role of microbes, particularly Borrelia bacteria and other spirochetes, in the onset of neurodegenerative diseases. The hypothesis is that molecules released by these bacteria (e.g. Borrelia; the bacterial infection that leads to Lyme disease) may interact with proteins in human brain which are involved in Alzheimer’s disease (AD) progression, promoting the formation of clumps (scientifically referred to as plaques) of the protein amyloid-beta, that form in the spaces between nerve cells in the brain, leading to cognitive decline. The research involves cultivating Borrelia bacteria strains, isolating and characterising their secretions, and applying computational modelling to identify molecules with potential pathogenic interactions. Lead candidates will be chemically synthesised in the lab and tested using the in-vitro blood-brain barrier (BBB) human tissue model developed in Project area 2.
Project area 2 aims to develop a robust, physiologically accurate in-vitro model of the barrier between blood and brain. Traditional 2D tissue models on flat surfaces, are limited in their ability to replicate the complexity of the blood-brain barrier (BBB) BBB, so the team has been creating a 3D BBB-on-a-chip using proprietary nanometre scale tubular scaffolds embedded in a microfluidic “organ-on-chip” device. This model reflects the true BBB’s vascular nature, enabling dynamic media flow and real-time monitoring of barrier integrity. The team also use human endothelial cells, astrocytes and pericytes, co-culturing them on opposite sides of the scaffold to accurately simulate the BBB environment in the device. This NTU patented, innovative platform will be used to screen therapeutic molecules and validate drug delivery strategies, offering a scalable and animal-free alternative for neurodegenerative research within NTU and beyond.
Project Area 3 explores the use of non-invasive technologies, including focused ultrasound (FUS) and red-light therapy (Photobiomodulation) to stimulate brain activity, improve drug delivery and cellular rejuvenation. These modalities have already shown promise in reversing memory loss and reducing amyloid plaques in animal models, but more research is needed to better understand how they work. The NTU team is developing a FUS device integrated with clinical magnetic resonance imaging (MRI), aiming to use these techniques in conjunction with nanobubbles, that can be loaded with therapeutic drugs, to temporarily permeabilise a small area of the BBB and promote passage of therapeutic treatment to the specific site of action. The BBB-on-chip model will be used to test and optimise the settings before progressing to in-vivo trials. The team are also developing a Photobiomodulation device, as a therapy which is reported to promote cell rejuvenation and tissue repair, to speed up the recovery of the BBB integrity after use of FUS.
Project area 4 investigates the therapeutic potential of human stem cell-derived therapeutics for neuroprotection and regeneration. Mesenchymal stem cells naturally release extracellular vesicles (EVs) that contain proteins, lipids and nucleic acids. The NTU team has identified over twenty candidate molecules with potential neuroprotective properties that can travel through the bloodstream and reach the brain. These potential therapeutics will be validated in the BBB-on-chip model and incorporated into delivery systems such as lipid nanobubbles. The aim is to develop targeted therapies that can bypass or cross the BBB and repair neuronal damage, offering a promising avenue for treating AD and other neurodegenerative diseases.
Together, these project areas form a comprehensive and multidisciplinary approach to understanding and fighting against neurodegenerative diseases. The project integrates microbiology, bioengineering, imaging, pharmacology and stem cell therapies, with strong commercial and collaborative potential. NTU has already filed patents and engaged with industry partners to translate these innovations into real-world applications. The ultimate goal is to develop effective, non-invasive treatments that can be routinely used to improve the lives of those affected by Alzheimer’s, Dementia and Parkinson’s disease.
Borrelia: a group of bacteria with a typical spiral-corkscrew shape, which is why they are also called spirochetes. They are mostly known as the cause of Lyme disease and other pathologies like relapsing fever, which are caught through bites from infected ticks or lice. Amyloid-beta plaques: amyloid-beta (Aβ) is a small protein which is naturally produced in our brain. However, excessive amounts are produced during the development of Alzheimer’s disease, leading to Aβ accumulation outside of brain cells to form clumps called plaques. These are toxic and damage the brain over time, causing neurodegeneration. Blood-Brain barrier (BBB): a filter between blood and brain, stopping potential toxins or pathogens present in the bloodstream from reaching and damaging the brain. It is formed by three main cell types: endothelial cells which form the walls of the blood vessel, pericytes which wrap around the vessel and astrocytes, star-shaped cells which support neurons and ensure brain health. In vitro: scientific term that refers to work done in the laboratory, where live cells are grown in plastic vessels (like petri dishes or flasks) outside of the live organism they originate from. It is opposed to in vivo experiments, which are carried out in live animal models or humans. Nanofibres scaffold: a web-like framework formed by interconnected nanometre scale threads which provide support for growing cells in 3D. We can make these scaffolds either flat (like a multi-layered nanofibres disc where cells of the BBB are grown on opposite sides) or folded in the shape of a tube to better mimic the blood vessels natural architecture. Organ-on-chip: innovative devices that mimic human organs in the lab. They are usually made with clear and flexible materials (providing the general structural support), a network of tiny channels which allow flow of liquids through the chip mimicking the bloodstream (microfluidic system), and growth chambers where human cells grow to form a simplified miniaturised organ. They are becoming more used in research as a viable alternative to animal experimentations for drug testing. Focused ultrasound (FUS): a technique that concentrates sound waves to a single point, similarly to what a magnifying glass can do with sunlight. The concentrated sound beams can heat/disrupt cells at the point of focus, without damaging the surrounding tissue. This non-invasive approach is used to treat targets inside the body like tumours, without recurring to traditional surgery. In the neurodegeneration field, FUS is being studied for its ability to target specific brain regions and potentially reduce amyloid plaque formation. Red-light therapy (Photobiomodulation): non-invasive therapy that uses red light to boost cells’ energy, promoting tissue repair. This approach is already used for several applications, including skin regeneration, pain relief and speeding up recovery of damaged tissues. Magnetic Resonance Imaging (MRI): medical imaging technique which allows to obtain detailed images of soft tissues like the brain or other organs, mostly used for diagnostic applications. In relation to FUS, MRI is used to guide the beam and ensure accuracy when targeting the desired location within the brain. Nanobubbles: gas filled biocompatible spheres that are injected in the bloodstream without causing any damage. When FUS is applied, these bubbles contracts and expand at the focus point, temporarily damaging the BBB and allowing drugs to pass through and reach the brain. Nanobubbles, especially lipid-based ones, can also be used as a delivery system to transport drugs through the bloodstream and designed so that they release the therapeutic molecule at the target site only. Stem cells: the cells in our body which can turn into many different cell types, using a process called differentiation. Mesenchymal Stem cells are a specific type of adult stem cells located in the bone marrow, fat tissue and umbilical cord, and they can differentiate in bone, cartilage, muscle, or fat cells. They are known to have neuroprotective potential. Extracellular vesicles (EVs): small bubble-like shuttles released by all cells in the body. They carry a variety of molecules (proteins, lipids, RNAs) and are used by cells to communicate with each other’s. Mesenchymal stem cells release a lot of EVs, and some of their content is known to have neuroprotective functions, suggesting that they could be a source of new potential therapeutic molecules to treat neurodegenerative diseases. |
How you can support Alzheimer’s, Dementia and Parkinson's research
Over the next three years, we’re fundraising £500,000 to continue our work. These gifts are fundamental to our development, helping us to grow our team, broaden our perspectives and expertise, and access world-class research tools and technology.
Re:searchers Re:vealed – meet our researchers
Forget lab coats and research papers. It's time to get personal. Meet the people behind the research and uncover fascinating truths about their experiences.
ADP Research Team
Professor Gareth Cave
Professor Gareth Cave leads the Alzheimer’s, Dementia and Parkinson’s research team. He specialises in nanotechnology, applying it across health, agriculture and materials science. His work focuses on creating sustainable nanomaterials for human health – from medical imaging and targeted drug delivery to new approaches for neurodegenerative diseases – alongside innovative solutions for animal health and wellbeing.
Dr Elisa Tonoli
Dr Elisa Tonoli is a Senior Research Fellow in the Chemistry and Forensics Department and a lecturer in the Department of Biosciences. She is also one of the project leads of the Eranda Rothschild founded project, and has collaborated with the Alzheimer's, Dementia and Parkinson's research team since 2021.
Professor Elisabetta Verderio Edwards
Dr Samantha McLean
Dr Biola Egbowon
Professor Rob Morris
Related staff
- Lorena Lizarraga
- Manisha Chennu
- Aadarsh Mishra
- Dr Jim Hall
- Mia Horton
- Michael Joseph